Path Grand Rounds: Bladder Cancer: Translational Research - New Answers to Old Problems

This event has ended.

Speaker

Funda Vakar-Lopez, MD
Assistant Professor
Department of Pathology
University of Washington


Date & Time

June 3, 2015 at 12:00pm - 1:00pm

Location

UWMC, NE110 conference room

Calendar

Path Grand Rounds

Export
Add to Calendar 06/03/2015 12:00 PM 06/03/2015 01:00 PM America/Los_Angeles Path Grand Rounds: Bladder Cancer: Translational Research - New Answers to Old Problems Path Grand Rounds: Bladder Cancer: Translational Research - New Answers to Old Problems

Funda Vakar-Lopez, MD
Assistant Professor
Department of Pathology
University of Washington
Why Attend? "Is this atypical urothelium neoplastic?" "Is the tumor invading muscularis porpria or muscularis mucosa?" Pathologists struggle with these questions regularly. These questions are just a few examples of the many aspects of bladder carcinoma that could be challenging. Urothelial carcinoma of the bladder is the second most common GU cancer with significant morbidity and mortality and limited treatment options. Despite its prevalence and significant negative impact on health, bladder cancer has been relatively understudied. The challenges include morphologic and clinical heterogeneity of the disease and subsequent varied disease outcomes. While the association of certain carcinogens in tumor development is well established, the mechanisms of their effect have not been identified. Developing informative animal models has the potential to improve our understanding of bladder cancer progression and its treatment. In this presentation, I shall review our current and future efforts at UW, Fred Hutchinson Cancer Center and Seattle Cancer Care Alliance addressing these challenges. Reference: PMID 25533674, PMID 25533675 Please Note: This lecture can also be viewed via teleconference: HMC: 2NJ251, VA: BD152, SCCA: G-3102
UWMC, NE110 conference room false MM/DD/YYYY
Recording
  View Event Recording

Description

Why Attend?

"Is this atypical urothelium neoplastic?" "Is the tumor invading muscularis porpria or muscularis mucosa?" Pathologists struggle with these questions regularly. These questions are just a few examples of the many aspects of bladder carcinoma that could be challenging. Urothelial carcinoma of the bladder is the second most common GU cancer with significant morbidity and mortality and limited treatment options. Despite its prevalence and significant negative impact on health, bladder cancer has been relatively understudied. The challenges include morphologic and clinical heterogeneity of the disease and subsequent varied disease outcomes. While the association of certain carcinogens in tumor development is well established, the mechanisms of their effect have not been identified. Developing informative animal models has the potential to improve our understanding of bladder cancer progression and its treatment. In this presentation, I shall review our current and future efforts at UW, Fred Hutchinson Cancer Center and Seattle Cancer Care Alliance addressing these challenges.

Reference: PMID 25533674, PMID 25533675